COLLPLANT BIOTECHNOLOGIES LT (CLGN) Stock Fundamental Analysis
USA - NASDAQ:CLGN - IL0004960188 - Common Stock
2.16 USD
-0.03 (-1.37%)
2.12 USD
-0.04 (-1.85%)
CLGN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. CLGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CLGN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CLGN had negative earnings in the past year.
CLGN had a negative operating cash flow in the past year.
CLGN had negative earnings in 4 of the past 5 years.
CLGN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -74.57%, CLGN is doing worse than 65.17% of the companies in the same industry.
CLGN's Return On Equity of -103.98% is in line compared to the rest of the industry. CLGN outperforms 44.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -74.57% | ||
| ROE | -103.98% | ||
| ROIC | N/A |
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CLGN has a better Gross Margin (61.78%) than 78.84% of its industry peers.
CLGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.78% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLGN has about the same amount of shares outstanding.
The number of shares outstanding for CLGN has been increased compared to 5 years ago.
There is no outstanding debt for CLGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CLGN has an Altman-Z score of -7.85. This is a bad value and indicates that CLGN is not financially healthy and even has some risk of bankruptcy.
CLGN's Altman-Z score of -7.85 is on the low side compared to the rest of the industry. CLGN is outperformed by 68.91% of its industry peers.
There is no outstanding debt for CLGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.85 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
A Current Ratio of 4.60 indicates that CLGN has no problem at all paying its short term obligations.
CLGN has a Current ratio (4.60) which is in line with its industry peers.
A Quick Ratio of 4.40 indicates that CLGN has no problem at all paying its short term obligations.
With a Quick ratio value of 4.40, CLGN perfoms like the industry average, outperforming 50.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.6 | ||
| Quick Ratio | 4.4 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 16.91% over the past year.
CLGN shows a strong growth in Revenue. In the last year, the Revenue has grown by 248.62%.
Measured over the past years, CLGN shows a very negative growth in Revenue. The Revenue has been decreasing by -25.99% on average per year.
EPS 1Y (TTM)16.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.32%
Revenue 1Y (TTM)248.62%
Revenue growth 3Y-67.95%
Revenue growth 5Y-25.99%
Sales Q2Q%-28.11%
3.2 Future
Based on estimates for the next years, CLGN will show a very strong growth in Earnings Per Share. The EPS will grow by 25.70% on average per year.
The Revenue is expected to grow by 103.99% on average over the next years. This is a very strong growth
EPS Next Y77.99%
EPS Next 2Y40.31%
EPS Next 3Y25.7%
EPS Next 5YN/A
Revenue Next Year428.63%
Revenue Next 2Y211.49%
Revenue Next 3Y103.99%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CLGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLGN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CLGN's earnings are expected to grow with 25.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.31%
EPS Next 3Y25.7%
5. Dividend
5.1 Amount
No dividends for CLGN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.16
-0.03 (-1.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners17.04%
Inst Owner Change2.1%
Ins Owners29.91%
Ins Owner ChangeN/A
Market Cap27.48M
Revenue(TTM)2.40M
Net Income(TTM)-13003000
Analysts82.5
Price Target11.73 (443.06%)
Short Float %1.97%
Short Ratio1.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-157.35%
Min EPS beat(2)-218.63%
Max EPS beat(2)-96.08%
EPS beat(4)0
Avg EPS beat(4)-91.66%
Min EPS beat(4)-218.63%
Max EPS beat(4)-21.21%
EPS beat(8)0
Avg EPS beat(8)-103.42%
EPS beat(12)1
Avg EPS beat(12)184.91%
EPS beat(16)1
Avg EPS beat(16)105.37%
Revenue beat(2)0
Avg Revenue beat(2)-58.47%
Min Revenue beat(2)-93.1%
Max Revenue beat(2)-23.83%
Revenue beat(4)0
Avg Revenue beat(4)-69.69%
Min Revenue beat(4)-99.06%
Max Revenue beat(4)-23.83%
Revenue beat(8)0
Avg Revenue beat(8)-74.64%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)616.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)75.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 11.44 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.2 | ||
| P/tB | 2.22 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS0.19
BVpS0.98
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -74.57% | ||
| ROE | -103.98% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.78% | ||
| FCFM | N/A |
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 21.75% | ||
| Cap/Sales | 8.78% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.6 | ||
| Quick Ratio | 4.4 | ||
| Altman-Z | -7.85 |
F-Score4
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)85.11%
Cap/Depr(5y)108.12%
Cap/Sales(3y)180.83%
Cap/Sales(5y)112.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.32%
EPS Next Y77.99%
EPS Next 2Y40.31%
EPS Next 3Y25.7%
EPS Next 5YN/A
Revenue 1Y (TTM)248.62%
Revenue growth 3Y-67.95%
Revenue growth 5Y-25.99%
Sales Q2Q%-28.11%
Revenue Next Year428.63%
Revenue Next 2Y211.49%
Revenue Next 3Y103.99%
Revenue Next 5YN/A
EBIT growth 1Y27.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.33%
OCF growth 3YN/A
OCF growth 5YN/A
COLLPLANT BIOTECHNOLOGIES LT / CLGN FAQ
What is the fundamental rating for CLGN stock?
ChartMill assigns a fundamental rating of 3 / 10 to CLGN.
Can you provide the valuation status for COLLPLANT BIOTECHNOLOGIES LT?
ChartMill assigns a valuation rating of 1 / 10 to COLLPLANT BIOTECHNOLOGIES LT (CLGN). This can be considered as Overvalued.
Can you provide the profitability details for COLLPLANT BIOTECHNOLOGIES LT?
COLLPLANT BIOTECHNOLOGIES LT (CLGN) has a profitability rating of 1 / 10.
What is the financial health of COLLPLANT BIOTECHNOLOGIES LT (CLGN) stock?
The financial health rating of COLLPLANT BIOTECHNOLOGIES LT (CLGN) is 6 / 10.